U.S. patent application number 11/017733 was filed with the patent office on 2005-07-21 for hybrid cells.
This patent application is currently assigned to GREENVILLE HOSPITAL SYSTEM. Invention is credited to Wagner, Thomas E., Wei, Yanzhang.
Application Number | 20050158244 11/017733 |
Document ID | / |
Family ID | 22640013 |
Filed Date | 2005-07-21 |
United States Patent
Application |
20050158244 |
Kind Code |
A1 |
Wagner, Thomas E. ; et
al. |
July 21, 2005 |
Hybrid cells
Abstract
A rapid, simple-to-use method for preparing hybrid cells,
applicable to fully differentiate, non-dividing cells, entails
bringing at least two different cells into contact under conditions
that promote cell fusion and then purifying the resultant hybrid
without antibiotic or metabolic selection. This approach yields
hybrid cells useful in a variety of applications, including
clinical treatment regimens, as cellular modulators of the immune
system.
Inventors: |
Wagner, Thomas E.; (Greer,
SC) ; Wei, Yanzhang; (Greer, SC) |
Correspondence
Address: |
FOLEY AND LARDNER
SUITE 500
3000 K STREET NW
WASHINGTON
DC
20007
US
|
Assignee: |
GREENVILLE HOSPITAL SYSTEM
|
Family ID: |
22640013 |
Appl. No.: |
11/017733 |
Filed: |
December 22, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11017733 |
Dec 22, 2004 |
|
|
|
09756293 |
Jan 9, 2001 |
|
|
|
6849451 |
|
|
|
|
60175376 |
Jan 11, 2000 |
|
|
|
Current U.S.
Class: |
424/9.6 ;
424/184.1; 424/85.2; 435/366; 514/414; 604/20 |
Current CPC
Class: |
A61K 35/13 20130101;
A61P 31/04 20180101; A61P 33/10 20180101; A61K 38/2013 20130101;
A61P 3/10 20180101; A61P 37/04 20180101; A61K 2039/5154 20130101;
A61P 37/02 20180101; A61P 33/04 20180101; A61P 37/06 20180101; A61P
35/00 20180101; A61P 31/00 20180101; A61K 2039/5152 20130101; A61P
33/00 20180101; C12N 5/163 20130101; A61P 37/00 20180101; A61P
31/10 20180101; A61P 33/02 20180101; A61P 43/00 20180101; A61K
35/15 20130101; C12N 5/16 20130101; A61K 38/2013 20130101; A61K
2300/00 20130101; A61K 35/15 20130101; A61K 2300/00 20130101; A61K
35/13 20130101; A61K 2300/00 20130101 |
Class at
Publication: |
424/009.6 ;
424/085.2; 514/414; 435/366; 604/020; 424/184.1 |
International
Class: |
A61K 039/00; A61K
049/00; A61K 038/20; A61K 031/405; C12N 005/08 |
Claims
1.-28. (canceled)
29. A composition comprising a hybrid cell preparation, wherein the
hybrid cell preparation is prepared by a method comprising: (a)
staining a neoplastic cell population freshly isolated from a
patient with a first marker, (b) staining a dendritic cell
population with a second marker, wherein the first marker is
different from the second marker, (c) contacting the neoplastic
cell population and the dendritic cell population with one another
under conditions that promote cell fusion, (d) obtaining a
resultant hybrid cell population stained with both the first and
second markers, and (e) purifying the resultant hybrid cell
population; wherein the method does not involve antibiotic or
metabolic selection, the purifying is accomplished in less than
about 24 to 48 hours after said contacting.
30. The composition of claim 29, wherein the first marker is a
fluorescent dye, the second marker is a fluorescent dye, and the
resultant hybrid cell population is purified by fluorescence
activated cell sorting.
31. The composition of claim 29, wherein the resultant hybrid cell
population contains less than 10% of its total population as
reactant cells.
32. The composition of claim 29, wherein the resultant hybrid cell
population contains less than 5% of its total population as
reactant cells.
33. The composition of claim 29, further comprising a
pharmaceutically acceptable vehicle.
34. The composition of claim 30, wherein the first and second
fluorescent dyes are endotoxin-free, pyrogen-free or both.
35. The composition of claim 29, wherein the neoplastic cell is a
tumor cell.
36. The composition of claim 35, wherein the tumor cell is a
primary tumor cell.
37. A method of treating cancer, comprising: (i) providing a hybrid
cell preparation prepared by a method comprising: (a) staining a
neoplastic cell population freshly isolated from a patient with a
first marker, (b) staining a dendritic cell population with a
second marker, wherein the first marker is different from the
second marker, (c) contacting said neoplastic cell population and
the dendritic cell population with one another under conditions
that promote cell fusion, (d) obtaining a resultant hybrid cell
population stained with both the first and second markers, and (d)
purifying the resultant hybrid cell population; wherein the method
does not involve antibiotic or metabolic selection, said purifying
is accomplished in less than about 24 to 48 hours after the
contacting; (ii) resuspending the resultant hybrid cell preparation
in a pharmaceutically acceptable vehicle, and (iii) administering
the hybrid cell preparation to a cancer patient.
38. The method of claim 37, wherein the first marker is a
fluorescent dye, the second marker is a fluorescent dye, and the
resultant hybrid cell population is purified by fluorescence
activated cell sorting.
39. A cancer vaccine comprising a hybrid cell preparation and a
pharmaceutically acceptable vehicle, wherein the hybrid cell
preparation is prepared by a method comprising: (a) staining a
neoplastic cell population freshly isolated from a patient with a
first marker, (b) staining a dendritic cell population with a
second marker, wherein the first marker is different from the
second marker, (c) contacting the neoplastic cell population and
the dendritic cell population with one another under conditions
that promote cell fusion, (d) obtaining a resultant hybrid cell
population stained with both the first and second markers, (e)
purifying the resultant hybrid cell population, and (f)
resuspending the resultant hybrid cell population in a
pharmaceutically acceptable vehicle; wherein the method does not
involve antibiotic or metabolic selection, the purifying is
accomplished in less than about 24 to 48 hours after the
contacting.
40. The cancer vaccine of claim 39, wherein the first marker is a
fluorescent dye, the second marker is a fluorescent dye, and the
resultant hybrid cell population is purified by fluorescence
activated cell sorting.
41. The cancer vaccine of claim 39, wherein the pharmaceutically
acceptable vehicle is saline.
42. A tumor vaccine comprising a hybrid cell preparation and a
pharmaceutically acceptable vehicle, wherein the hybrid cell
preparation is prepared by a method comprising: (a) staining a
neoplastic cell population freshly isolated from a patient with a
first marker, (b) staining a dendritic cell population with a
second marker, wherein the first marker is different from the
second marker, (c) contacting the neoplastic cell population and
the dendritic cell population with one another under conditions
that promote cell fusion, (d) obtaining a resultant hybrid cell
population stained with both the first and second markers, (e)
purifying the resultant hybrid cell population, and (f)
resuspending the resultant hybrid cell population in a
pharmaceutically acceptable vehicle; wherein the method does not
involve antibiotic or metabolic selection, the purifying is
accomplished in less than about 24 to 48 hours after the
contacting.
43. The tumor vaccine of claim 42, wherein the first marker is a
fluorescent dye, the second marker is a fluorescent dye, and the
resultant hybrid cell population is purified by fluorescence
activated cell sorting.
44. The tumor vaccine of claim 42, wherein the pharmaceutically
acceptable vehicle is saline.
45. A method for treating an autoimmune disease, comprising: (i)
preparing a hybrid cell preparation prepared by a method comprising
(a) contacting a population of target cells with a first marker,
(b) contacting a population of antigen presenting cells lacking an
accessory molecule with a second marker, (c) contacting said target
cells and said antigen presenting cells deficient in an accessory
interaction under conditions that promote cell fusion, (d)
obtaining a resultant hybrid cell population stained with both the
first and second markers, and (e) purifying the resultant hybrid
cell population; and (f) resuspending the resultant hybrid cell
population in a pharmaceutically acceptable vehicle, wherein said
method does not involve antibiotic or metabolic selection; (ii)
resuspending the resultant hybrid cell preparation in a
pharmaceutically acceptable vehicle, and (iii) administering the
hybrid cell preparation.
46. A method of preparing a formulation for tolerizing an immune
system against a target cell comprising: (a) contacting a
population of target cells with a first marker, (b) contacting a
population of antigen presenting cells lacking an accessory
molecule with a second marker, (c) contacting said target cells and
said antigen presenting cells deficient in an accessory interaction
with one another under conditions that promote cell fusion, (d)
obtaining a resultant hybrid cell population stained with both the
first and second markers, (e) purifying the resultant hybrid cell
population by cell sorting, and (f) resuspending the resultant
hybrid cell population in a pharmaceutically acceptable buffer;
wherein said cell sorting does not involve antibiotic or metabolic
selection.
47. The method of claim 46, wherein the first marker is a
fluorescent dye, the second marker is a fluorescent dye, and the
resultant hybrid cell population is purified by fluorescence
activated cell sorting.
48. A kit comprising (i) at least two dyes that are essentially
endotoxin-free and (ii) instructions for preparing hybrid cells
from reactant cells by a method comprising: (a) staining a
neoplastic cell population freshly isolated from a patient with a
first dye, (b) staining a dendritic cell population with a second
dye, wherein said first dye is different from said second dye, (c)
contacting said neoplastic cell population and said dendritic cell
population with one another under conditions that promote cell
fusion, (d) obtaining a resultant hybrid cell population stained
with both the first and second dyes, and (e) purifying the
resultant hybrid cell population; wherein said method does not
involve antibiotic or metabolic selection, said purifying is
accomplished in less than about 24 to 48 hours after said
contacting.
Description
BACKGROUND OF THE INVENTION
[0001] The present invention relates to hybrid cells and methods of
making and using hybrid cells. Perhaps the most substantial
practical application of hybrid cells is the production of
hybridomas, which are used to produce monoclonal antibodies. In
addition, they are used in a variety instances for research
purposes, but their broader application, for example, in a clinical
treatment setting has heretofore not been practical. These clinical
applications include the cellular vaccines for treating or
preventing cancer and other disorders, as well as preventing
transplant rejection. The present invention responds to such
deficiencies by providing methods and reagents that make the broad
applicability of hybrid cells a reality.
[0002] Although a cancer treatment goal for more than half a
century, recent advances in molecular immunology now make
immunotherapy a truly viable option for the treatment of patients
with cancer and metastatic disease. The past decade has seen the
approval and introduction of several immunotherapeutic strategies
for wide ranging use against several metastatic cancers, Parkinson
et al, in CANCER MEDICINE, 4.sup.th ed., pp. 1213-1226 (Holland et
al., eds. 1997). Perhaps the best known strategies include IL-2
therapy (Philip et al., Seminars in Oncology. 24(1 Suppl 4): S32-8,
1997 February) and tumor vaccines targeted against melanoma. Smith
et al., Int J Dermatol 1999; 38(7): 490-508. While these strategies
are efficacious against some tumors, their potency is limited
because they only enhance the already enfeebled ability of tumor
cells to present their "foreign" epitopes to CD8 T-cells, and to
generate thereby a tumor-specific cytotoxic T lympocyte (CTL)
response.
[0003] Autologous whole tumor cell-based vaccines were first used
for immunotherapy of malignant melanoma. Such whole tumor
cell-based vaccines are advantageous, because they contain large
numbers of antigens, which eliminates the need for targeting the
immune response against one antigen at a time. This is important
because currently there is little ability to identify specific
tumor-associated antigens (TAA) that are useful to induce immune
system-mediated tumor regression. Boon et al., Immunol Today 1997;
18:267-268. To date, however, autologous whole tumor cell-based
vaccines alone have shown only some isolated or marginal successes.
Smith et al., supra. As seen below, the marginal success of whole
tumor cell-based vaccines likely results from tumor cell mutations
that impair their ability to act as antigen presenting cells
("APCs").
[0004] Evidence from many tumor immunology laboratories
demonstrates that tumor cells persist in part because they have
selected a mutation which partially or completely destroys their
ability to act as APCs in the process of cytotoxic T lymphocyte CTL
generation. Stockert et al., J. Exp. Med. 1998; 187: 1349-1354;
Sahin et al., Proc. Natl Acad. Sci. USA 1995; 92:11810-11813;
Gabrilovich et al., Nature Med. 1996; 2:1096-1103; Ishida et al.,
J. Immunol. 1998; 161:4842-4851. These observations spurred
development of strategies that attempt to replace the tumor cell as
the APC, rather than trying to boost the tumor's enfeebled antigen
presenting process. The best candidate for such a replacement is
the dendritic cell ("DC").
[0005] DCs are "professional" antigen presenting cells that play a
vital role in stimulating immune responses. DCs not only can
activate naive CD4+ T helper cells but also stimulate unprimed CD8+
cytotoxic T lymphocytes. Steirnan, R. M. Annu. Rev. Immunol. 1991;
9, 271-296; Macatonia, et al., J. Exp. Med. 1988; 169, 1255-1264;
Mehta-Damaniet al., J. Immunol. 1994;153, 996-1003; Porgador et
al., J. Exp. Med. 1995;182, 255-260.
[0006] Because of these characteristics, DCs have been widely
studied as antigen presenting cells for cancer immunotherapy. DCs
can be loaded with tumor antigens by pulsing with whole tumor
antigens or tumor antigen peptides. Young et al., J. Exp. Med.
1996; 183, 7-11; Mayordoma et al., Nat. Med. 1995; 1, 1297-1302;
Bakkar et al., Cancer Res. 1995; 55, 5330-5334; Flamand et al.,
Eur. J Immunol. 1994; 24, 605-610; Gong et al., Gene Ther. 1997; 4,
1023-1028; Song et al., J. Exp. Med. 1997;186, 1247-1256; Specht et
al. J. Exp. Med. 1997;186, 1213-1256.
[0007] Peptide- or tumor lysate-pulsed dendritic cells have been
used, for example, to vaccinate melanoma patients. Rosenberg et
al., Nature Med 1998; 4: 321-327; Wallack et al., Cancer 1995;
75:34-42; Bystryn, Rec. Results Cancer Res. 1995; 139:337-348;
Mitchell et al., Semin. Oncol. 1998; 25: 623-635; Morton et al.,
Ann. N.Y. Acad. Sci. 1993; 690:120-134; Berd et al., Semin Oncol.
1998; 25:646-653; Berd et al., J. Clin. Oncol. 1997;
15:2359-2370.
[0008] Tumor antigen-loaded DCs so loaded with tumor antigens are
able to induce both cellular and humoral, antigen-specific,
anti-tumor immune responses. Shurin, M. R. Cancer Immunol.
Immunother. 1996; 43, 158-164. This approach, however, is limited
to application against tumors expressing known tumor antigens. See,
Haigh et al., Oncology 1999; 13, 1561-1573. It is worthless for
those tumors with no identified tumor antigen, like primary tumors
from patients, which constitute most real-world situations.
Obviously alternative strategies are needed.
[0009] An additional problem with antigen pulsing techniques is
that the antigen presenting system of an APC works more effectively
and efficiently when the protein/antigen is synthesized inside the
cell rather than outside the cell, a substantial drawback to using
antigen-pulsed cells. In an effort to avoid this problem, a number
of laboratories have attempted to use gene therapy to introduce
specific tumor antigens into dendritic cells. Gong et al.,,
1997,Gene Ther. 4, 1023-28; Song et al., 1997, J. Exp. Med. 186:
1247-56; and Specht et al., 1997, supra.. However, this gene
therapy approach is also fraught with many disadvantages including:
1) the limited ability to identify all of the important specific
tumor antigens, 2) the limited ability to map the genes of the
specific tumor antigens, 3) only one or a small number of the known
tumor antigen genes can be introduced into the dendritic cell and
4) the process is time-consuming and cumbersome.
[0010] On the other hand, fusions between DCs and tumor cells
represents an alternative way to produce effective tumor antigen
presenting cells by presenting the immune cells with all possible
tumor antigens. Gong et al., Nat. Med. 1997; 3: 558-561; Wang et
al., J. Immunol. 1998;161, 5516-5524; Lespagnard et al., Int. J.
Cancer 1998; 76, 250-258; Rowse et al, Cancer Res. 1998; 58,
315-321. DCs have been fused with tumor cells and the fused cells
efficiently presented tumor antigens to the immune cells and
stimulated a specific anti-tumor immune responses. Gong et al.;
Wang et al.; Lespagnard et al., all supra.
[0011] These fusion schemes, however, rely on selectable markers
(gene products which render the cell resistant to specific cell
toxins or allow them to grow under certain metabolic conditions) in
each of the DCs and the tumor cells to isolate the resultant
hybrid. The rare cell fusion products are selected by long-term
culture in the presence of both cell toxins where only the fusion
product, containing both selectable markers, can survive. Since the
introduction and selection schemes using markers requires culture
and multiple cell division, they cannot be applied to dendritic
cells, because DCs are terminally differentiated, non-dividing
cells. Thus, it is no surprise that the previous fusion work relied
on well-defined tumor cell lines, bearing such a marker, and DC-
and tumor-specific conjugated antibodies, which limits the
usefulness of this strategy in cancer treatment.
[0012] In summary, the previous cancer-based fusion protocols have
the following limitations: 1) they require established tumor cell
lines which show specific marker(s); 2) they require both DC and
tumor cll specific antibodies to select the fused cells; 3) the
selection and expansion of the fused cells takes an impractical
amount of time.
[0013] The area of preventing transplant rejection using hybrids
are even less well-developed than cancer. In fact, no report of
such has been found.
[0014] Typical approaches to preventing transplant rejection
utilize non-selective immunosuppressive drugs that suppress the
entire immune system. Abbas et al., CELLULAR AND MOLECULAR
IMMUNOLOGY, pp. 347-350. Such approaches have the obvious
disadvantage of making the patient more susceptible to disorders
that otherwise could have been warded off by an intact immune
system.
[0015] It has been recognized that at least two interactions must
take place in order for an antigen presenting cell to activate a T
cell. These interactions are between an antigen-loaded major
histocompatibility (MHC) antigen and the T cell receptor, and
between certain accessory molecules and their cognate receptors on
the T cell. The best studied class of these accessory molecules is
B7 (B7.1 and B7.2), which interact with CD28 and CTLA4 on T cells.
Abbas et al., supra. Thus, disruption of either the MHC or the
accessory interaction should result in a non-response useful, for
example, in preventing transplant rejection.
[0016] In fact, disruption of B7 interaction not only prevents an
immune response, it induces permanent tolerance to any antigen
presented during the disruption. Wei et al., 1996, Stem Cells 14:
232-38. Thus, in the context of transplant rejection, blocking B7
should result in tolerance, preventing rejection. The problem with
such an approach, and the likely reason that it has not be
attempted clinically, is that tolerance would pertain to any
antigen presented during treatment, not just to transplant
antigens. In other words, if a patient were exposed to a pathogen
during the B7 disruption, the patient's immune system would be
rendered tolerant to the pathogen, permanently. This would prevent
the patient from warding off the pathogen, having perhaps lethal
consequences. Clearly, a more specific approach is needed.
[0017] A promising approach takes advantage of antigen presentation
by cells that lack accessory molecules, like B7. These cells
present antigen in the context of MHC, yet, because they lack the
accessory interactions required for activation, they induce
tolerance specific to the antigen presented. Thus, it is possible
to load these cells, which include immature (nave) B cells, with a
specific antigen, and induce antigen-specific anergy. As with the
cancer example described above, this antigen-by-antigen approach
does not have the general applicability needed for practical
clinical use. A methodology is needed which is applicable to any
transplant organ, irrespective of the immunogenic antigens the
organ displays.
[0018] In view of the foregoing, it is evident that the art is in
need of generally applicable, rapid methods for inducing and
suppressing specific immune responses to whole cells and specific
reagents for accomplishing these methods.
SUMMARY OF THE INVENTION
[0019] It is, therefore, an object of the invention to provide
solutions to the aforementioned deficiencies in the art.
[0020] Further to this object, the invention provides a kit useful
in preparing hybrid cells. In one aspect, the kit contains at least
two essentially endotoxin-free dyes and instructions for preparing
hybrid cells from reactant cells by a method that entails
contacting reactant cells with one of said dyes, respectively. In
another aspect, the kit contains at least two essentially
endotoxin-free dyes and an agent that promotes cell fusion. The
endotoxin-free dyes are preferably fluorescent dyes, such as
cyanine dyes.
[0021] Also according to this object of the invention, a hybrid
cell preparation is disclosed. In one embodiment, the preparation
contains a hybrid cell having no more than n-1 selectable markers,
where n represents the number of reactant cells used to form the
hybrid and the preparation is substantially free of non-hybrid
cells. In another embodiment, the preparation contains a hybrid of
a primary tumor cell and an antigen presenting cell. In still
another embodiment, the preparation contains a hybrid of a normal
cell and an antigen-presenting cell which lacks an accessory factor
required to generate a positive immune response. The normal cell
may be isolated from a transplant organ. An additional embodiment
is a preparation containing a hybrid between a pathogenic cell and
an antigen-presenting cell, like a cell from parasite. One hybrid
cell preparation is composed of a hybrid cell labeled with at least
two different dyes, that are preferably fluorescent, like cyanine
dyes. The hybrid cell my be derived from, for example, a dendritic
cell or an immature B cell.
[0022] Still another aspect of the invention provided in accord
with this object is a method of preparing a hybrid cell. One
embodiment of the inventive method entails bringing at least two
different cells into contact under conditions that promote cell
fusion, and then purifying the resultant hybrid without the need
for antibiotic or metabolic selection. In one aspect the method is
accomplished using fluorescent dyes, like cyanine dyes, and the
hybrids are isolated by fluorescence activated cell sorting. The
methods can involve fusing reactant cell, like a macrophage, a
dendritic cell, and an antigen presenting cell that lacks an
accessory factor required to generate a positive immune response,
with a second reactant cell, like a tumor cell, a pathogenic cell
and a normal cell. The method is preferably accomplished in less
than about 48 hours.
[0023] In still another aspect, the invention provides a method of
treating cancer, that involves providing an inventive hybrid cell
preparation that is derived reactant cell that is a cancer cell;
and administering the hybrid cell to a cancer patient. The method
may include adjunct treatment with a cytokine or lymphokine, like
interleukin-2.
[0024] In yet another aspect, the invention contemplates a method
of treating a disorder associated with the presence of a pathogenic
organism that involves providing an inventive hybrid cell
preparation that is derived from a cell isolated from said
pathogenic organism and administering the cell to a patient. Again,
the method may include adjunct treatment with a cytokine or
lymphokine, like interleukin-2.
[0025] Also in accord with the object of the invention, the
invention provides a method of inducing immune tolerance to an
antigen that entails providing an inventive hybrid cell preparation
that is derived from a cell that expresses an antigen against which
immune tolerance is sought and administering said preparation to a
patient. The cell against which immune tolerance is sought may be a
cell from a transplant organ, where the patient needs an organ
transplant.
BRIEF DESCRIPTION OF THE DRAWINGS
[0026] FIG. 1 shows that hybrid cells according to the invention,
between dendritic cells and cancer cells are capable of generating
a tumor-specific cytotoxic T cell response, which is relevant to in
vivo immunotherapy.
[0027] FIG. 2A shows FACS-detection of antigen-presentation markers
on control dendritic cells. A normal distribution is shown.
[0028] FIG. 2B shows FACS-detection of antigen-presentation markers
on dendritic/tumor cell hybrids. A normal distribution is shown, as
compared to the control dendritic cells, meaning that the hybrid
cells retain all of the markers necessary for antigen
presentation.
DETAILED DESCRIPTION OF THE INVENTION
[0029] In one aspect, the present invention provides a rapid and
efficient method of preparing hybrid cells that are useful in a
variety of clinical and non-clinical applications. The hybrid cells
are particularly useful in treatment regimes that invoke the immune
system to treat or prevent disease. For instance, in a preferred
embodiment, the inventive hybrid cells are used to treat cancer by
fusing a cancer cell to an antigen presenting cell. In another
embodiment, the inventive hybrid cells comprise a plasma cell and a
cancer cell which, like conventional hybridomas, are useful in
preparing monoclonal antibodies. In still another embodiment, the
present hybrid cells comprise an antigen presenting cell that lacks
an accessory component needed for an immunogenic response and a
cell from an organ destined for transplant in a patient. These.
cells may be used to induce tolerance to the transplant cells,
thereby reducing the incidence of transplant rejection. Kits for
generating hybrid cells and for practicing the inventive methods
also are provided.
[0030] Method of Preparing Hybrid Cells
[0031] The present invention contemplates a method of preparing
hybrid cells that is rapid, simple to use, and applicable to fully
differentiate, non-dividing cells. The inventive approach involves
bringing at least two different cells ("reactant cells") into
contact under conditions that promote cell fusion, and then
purifying the resultant hybrid ("product cell") without antibiotic
or metabolic selection. In general, the purification is
accomplished in a relatively short period of time, for example, in
less than about 24 to 48 hours, after exposure to conditions that
promote fusion.
[0032] In a preferred embodiment, the method is accomplished with
the aid of at least two different dyes, which can be fluorescent
dyes. Thus, the method may entail separately contacting, each with
a different dye, the two cell types to be fused. This pre-fusion
labeling marks each cell with a different dye, and permits
discrimination among each fusion parent cell and the hybrid fusion
product: the reactant cells each are stained with one dye, and the
product cells are stained with both. This way, the hybrid fusion
product may be separated from the reactant cells, for example, by
fluorescence activated cell sorting (FACS), and the like.
[0033] Dyes useful according to the invention have the
characteristic of associating with a cell for a time sufficient to
detect them in such association. In addition, useful dyes do not
substantially diminish cell viability, with greater than about 50%
cell viability being preferred. Typically, they are fluorescent
dyes. One useful class of dyes comprises the so-called "cyanine"
dyes. Cyanine dyes come in a variety of types that fluoresce at
different wavelengths such that they can be individually or jointly
detected when associated with a cell. Some exemplary cyanine dyes
are found in Horan et al., U.S. Pat. No. 4,783,401 (1998), U.S.
Pat. No. 4,762,701 (1988) and U.S. Pat. No. 4,859,584 (1989), the
structures of which are hereby specifically incorporated by
reference.
[0034] Two particularly useful cyanine dyes are PKH26-GL and
PH2-GL, which may be obtained from the Sigma Chemical Co. These
dyes are preferred because they have been widely studied and used.
For instance, they have been used in animal studies in vivo for
cell trafficking studies. Horan et al., Nature 1989; 340, 167-168;
Horan et al., Methods Cell Biol. 1990; 33, 469-490; Michelson et
al., Proc. Natl. Acad. Sci. USA 1996; 93, 11877-11882. In
laboratory animals these dyes have been shown not to affect cell
growth or function and not to migrate from the cells stained with
these dyes to other cells (Horan et al., 1989), thus have low
toxicity, a desirable quality for in vivo applications.
[0035] Dyes employed in vivo in accordance with the present
invention should be free of endotoxin, as measured, for example, by
the Limulus amaebocyte (LAL) assay. Typically, when the measured
endotoxin level is less than about 1 ng/.mu.g dye, and preferably
less than about 0.1 ng/.mu.g dye, then the dye is considered
"endotoxin-free."
[0036] More generally, the dyes are essentially pyrogen-free,
whether pyrogenicity is contributed by endotoxin or other pyrogens.
Thus, a dye is considered "essentially pyrogen free" when the final
formulation of hybrid cells labeled with the dye (in a form to be
injected into a subject, for example) yields less than about 1
endotoxin unit (EU)/dose, but preferably less than about 0.1
EU/dose and most preferably less than about 0.05 EU/dose. Toxicity
thresholds are informed by the fact that most in vivo methods
contemplated herein result in less than about 10.sup.-8 g of these
dyes, in association with cells, being introduced into a patient
when undertaking the inventive methods of treatment.
[0037] Conventional cyanine dye labeling methodologies require the
presence of cellular stabilizers (osmolarity regulating agents),
like sugars (e.g., glucose or mannitol), amino acids and/or certain
Goods buffers. See, for example, Horan et al., U.S. Pat. No.
4,783,401 (1998). The inventors discovered that dimethyl sulfoxide
(DMSO) can substitute for such stabilizers. In particular, DMSO
diluted in a standard culture medium may be used as a solvent for
cyanine dyes, and it promotes efficient and stable uptake of dye
without substantial loss of cell viability. A generally useful
range of DMSO concentration is from about 10 to about 50%, but a
preferred range is from about 20 to about 40%. The invention
therefore also contemplates methods of labeling cells, and
corresponding kits, with cyanine dyes using DMSO in place of the
conventional stabilizers.
[0038] Once the reactant cells are labeled, they are put into
contact with one another, under conditions that promote fusion.
Such fusion-promoting conditions are well known to the artisan, and
typically involve the addition of an agent that promotes cell
fusion. These agents are thought to work by a molecular crowding
mechanism to concentrate cells to an extent that they are in close
enough proximity to cause fusion of cell membranes. While the
invention contemplates any agent that meets these characteristics,
exemplary useful agents are polymeric compounds, like polyethylene
glycols. An effective amount of such an agent generally will be
from about 20% to about 80% (w/v). A preferred range is from about
40% to about 60%, with about 50% being more preferred.
[0039] After hybrid cell formation, it is usually beneficial to
isolate them from the un-fused reactant cells. In the case of
cellular vaccines, for example, this purification substantially
increases the potency. Purification may be accomplished by
conventional FACS methodologies, for example.
[0040] The method explicitly contemplates hybrid cells of higher
order, which are fusions between more than two cells. In each case,
all that is needed is an additional dye that can serve as a marker
for selection of the higher-order hybrid. For example, three
different reactant cells labeled with three different dyes are used
to form a "tribred," and so on. Thus, as used herein, the term
"hybrid cell" contemplates fusions between two or more reactant
cells.
[0041] Kits of the Invention
[0042] The present invention also relates to kits for labeling
cells and for preparing hybrid cells. These kits are useful in
implementing the inventive method of preparing hybrid cells. A
labeling kit, for example, contains at least one dye, and may
contain DMSO and instructions for labeling. The inventive hybrid
cell preparation kit, comprises at least two essentially
endotoxin-free and/or pyrogen-free dyes and instructions for
preparing hybrid cells and/or it comprises an agent that promotes
cell fusion.
[0043] Hybrid Cell Preparations
[0044] The invention further contemplates a hybrid cell
preparation. In general, the preparation will be substantially free
of reactant cells (less than about 50% reactant cells, but
preferably less than about 10% to 25% reactant cells, and most
preferably less than about 5% reactant cells). The inventive hybrid
cells are prepared from reactant cells that may have a selectable
marker, but need not. In any event, at least one reactant cell
lacks such a marker. Thus, where n represents the number of
reactant cells, in most cases, n-1 will represent the maximum
number of selectable markers found in the hybrid cell. For example,
where two reactant cells fuse to form a hybrid, the hybrid will
contain no more than one selectable marker.
[0045] The phrase "selectable marker" is used here in its
conventional sense, to refer to an antibiotic resistance or a
metabolic marker, such as hypoxanthine phosphoribosyl transferase
(HPRT), and the like.. Selectable markers are endogenously
produced, and do not include exogenously added materials, like
dyes.
[0046] In one embodiment, the inventive hybrid cell preparation,
comprises a primary tumor cell and an antigen presenting cell (APC)
as reactants. Such hybrids may be used as cellular vaccines to
induce an immune response against a tumor. The tumor cell may be of
any type, including the major cancers, like breast, prostate,
ovarian, skin, lung, and the like. The APC preferably is a
professional APC, like a macrophage or a dendritic cell. Due to
their superior antigen presentation capabilities, dendritic cells
are more preferred. Both syngeneic and allogeneic fusions are
contemplated as the inventors have discovered using a mouse model
that both work equally well.
[0047] An additional embodied hybrid comprises a pathogenic cell
and an APC. These hybrids also are useful as cellular vaccines.
Again, antigen presenting cells, and dendritic cells, in
particular, are favored. The pathogenic cell, on the other hand,
may be of virtually any type. For example, it may be a bacterial
cell (Helicobacter, etc.) that has had its cell wall removed. The
pathogenic cell may be a fungal cell, like Candida, Cryptococcus,
Aspergillus and Alternaria.
[0048] The pathogenic cell also may be a parasitic cell from, for
example, trypanosomal parasites, amoebic parasites, miscellaneous
protozoans, nematodes, trematodes and cestodes. Exemplary genera
include: Plasmodium; Leishmania; Trypanosoma; Entamoeba; Naeglaria;
Acanthamoeba; Dientamoeba; Toxoplasma; Pneumocystis; Babesia;
Isospora; Cryptosporidium; Cyclospora; Giardia; Balantidium;
Blastocystis; Microsporidia; Sarcocystis; Wuchereria; Brugia;
Onchocerca; Loa; Tetrapetalonema; Mansonella; Dirofilaria; Ascaris
(roundworm); Necator (hookworm); Ancylostoma (hookworm);
Strongyloides (threadworm); Enterobius (pinworm); Trichuris
(whipworm); Trichostrongylus; Capillaria; Trichinella; Anasakis;
Pseudoterranova; Dracunculus; Schistosoma; Clonorchis; Paragonimus;
Opisthorchis; Fasciola; Metagonimus; Heterophyes; Fasciolopis;
Taenia; Hymenolepis; Diphyllobothrium; Spirometra; and
Echinococcus.
[0049] In another embodiment, the inventive hybrid cell preparation
comprises a target cell against which immune tolerance is desired
and an antigen presenting cell that lack accessory factor needed
for an immunogenic response. Typically these APCs lack B7 (e.g.,
B7.1 or B7.2); exemplary cells are naive, immature B cells and
fibroblasts, but any cell capable of presenting antigen (having MHC
molecules), yet lacking an accessory molecule, will suffice. In the
case of B7, specific antibodies are known, and the artisan will be
well apprised of methods to ascertain whether any particular cell
type lacks B7. Naive B cells are preferred because they express
high levels of MHC molecules and all the adhesive molecules known
in the art to be necessary for efficient cell-cell contact.
[0050] In any event, the resultant hybrids have the ability to
present antigen to the immune system, since they bear class I and
class II MHC molecules, yet they will not have the ability to
activate the immune system, since they do not have the necessary
accessory markers, like B7 (CD28 or FLTA4 ligands). Thus, instead
of inducing an immune response, these hybrids will induce apoptotic
clearance, thereby rendering the immune system tolerant to the
target, cell antigens presented by these hybrids. Such immune cell
hybrids are useful in treating autoimmune disorders like transplant
rejection.
[0051] The inventive hybrid cell preparation may be made using a
combination of dyes, as detailed above. Thus, the inventive hybrid
cell may be labeled with at least two different dyes. These dyes
are preferably fluorescent and, again, cyanine dyes are favored.
Alternatively, hybrid cells may be prepared, for example, using
cell surface markers differentially expressed on the reactant cells
and corresponding antibodies to them. The antibodies may be used to
pan sequentially for each marker. See, Gong et al., 1997, Nat. Med.
3: 558-61.
[0052] Methods of Treatment
[0053] The inventive methods and products are useful in methods of
treatment and prophylaxis, and "treatment" is used herein to
include "prophylaxis." Such a method basically involves
administering to a patient a hybrid between a "target" cell and a
second, typically antigen-presenting, cell. The "target" cell is
one against which an immune response is sought. The immune response
may be positive or negative, depending on the disorder to be
treated. For example, a positive immune response is desirable in
treating cancer or parasitic diseases, but a negative immune
response is desirable in preventing transplant rejection.
[0054] One embodied method of treatment or prophylaxis pertains to
cancer. This method entails administering to a patient an inventive
hybrid cell, or hybrid cells prepared by the inventive method or
kit. In one aspect, the administered hybrid cell has n-1 selectable
markers, as described above. The hybrid cell may be labeled with at
least two dyes.
[0055] An exemplary cancer treatment method involves labeling
isolated neoplastic and immune cells with different dyes and
forming a hybrid cell between the labeled cells. The hybrid cell is
isolated and administered to a patient in an acceptable excipient.
In order to avoid administration of viable cancer cells, it is
advisable to lethally irradiate the tumor reactant cells prior to
fusion. This step kills the cell, but does not prevent efficient
presentation of the tumor antigen(s) by the resultant hybrid cell.
Both syngeneic and allogeneic fusions are contemplated as the
inventors have discovered using armouse model that both work
equally well.
[0056] The cancer treatment may be augmented, moreover, by using
additional antineoplastic agents in conjunction with the hybrid
cells. One class of such agents is immunomodulators. These include
cytokines and lymphokines, especially interleukin-2 (IL-2) and IL-2
derivatives, like aldesleukin (Proleukin, Chiron Corp.). The use of
IL-2 is preferred because it should further enhance the immune
response generated by the hybrid cell. As used herein,
"interleukin-2" is used generically to refer to the native
molecules and any derivatives or analogs that retain essential
interleukin-2 activity, like promoting T cell growth. Other
lymphokines and cytokines may also be used as an adjunct to
treatment. Examples include interferon gamma (IFN-.gamma.),
granulocyte macrophage colony simulating factor (GM-CSF), and the
like.
[0057] A modification of the cancer treatment regimen can be used
to treat any disorder associated with a pathogenic organism. In
this modification, the reactant cells will be APCs and cells
isolated from the pathogenic organism. Otherwise, the treatment
would be accomplished as in cancer treatment.
[0058] A different aspect of the invention comprehends a method of
treating autoimmune disorders. The method is accomplished in
essentially the same manner as the cancer treatment set out above.
The primary difference being the identity of the reactant cells. In
the case of autoimmune disorders, the goal is to diminish or
eliminate an immune response, whereas in cancer treatment the goal
is to create or enhance an immune response.
[0059] The ability to use the inventive hybrids in treating
autoimmune disorders derives in part from the observation that
certain cells can present antigen, yet they lack the accessory
molecules to provide a positive immune response. Typically these
cells lack B7, and they may be immature B cells or fibroblasts, for
example. In fact, antigen presentation by such cells generates a
negative immune response. It tolerizes the immune system, inducing
apoptosis of specific antigen-reactive immune cells.
[0060] Thus, the method of treating autoimmune disorders utilizes
an APC, deficient in an accessory interaction, and a "normal cell"
as the reactants. The "normal cell" is any target cell to which
immune tolerance is desired. It may be from a transplant organ, for
example, in a method of preventing transplant rejection. In the
case of treating or preventing diabetes, by transplantation or
otherwise, on the other hand, the normal cell may be an Islet cell.
Such a method can be adapted to tolerize the immune system against
any type of cell.
[0061] As used herein, the term "treat" and its various forms also
encompasses prophylactic methods.
[0062] The foregoing detailed description and the following
examples are offered for illustrative purposes and are not meant to
be limiting. The artisan will recognize that there are additional
embodiments that fall within the invention, but are not described
with particularity.
EXAMPLES
Example 1
Animal Studies
[0063] This example demonstrates the preparation of certain hybrids
between cancer cells and dedritic cells, called dendritomas. These
hybrids are used as a cellular vaccine to prevent cancer in a
murine metastatic cancer model system.
[0064] To prepare dendritic cells from bone marrow, the appropriate
number of female C57BL/6J mice to support later Dendritoma
injections (two mice for every one mouse to be injected) were
sacrificed. The femur and tibia of both hind legs were removed from
each mouse. Bone marrow was flushed out of the bones using a
syringe containing RPMI 1640 with 25 mM Hepes (Gibco BRL). The
media containing the bone marrow was filtered through a 40 .mu.m
cell strainer into a 50 ml conical centrifuge tube. The bone marrow
cells were pelleted by centrifugation at 1500 rpm for five minutes.
After removing the supernatant, the tube was gently tapped to
loosen the cell pellet. Red blood cell lysis was achieved by adding
5 ml/mouse of ACK Lysing Solution (0.15 M NH.sub.4Cl, 1 mM
KHCO.sub.3, 0.1 mM Na2EDTA, pH 7.3) and incubating at room
temperature for five minutes. The cells were pelleted by
centrifugation at 1500 rpm for five minutes. The supematant was
removed, and the cells were gently resuspended in 10 ml/mouse of
complete DC media (RPMI 1640, 10% fetal bovine serum (FBS), 100
.mu.g/ml gentamicin, 10 ng/ml GM-CSF, 10 ng/ml IL4). The cells were
plated into two wells/mouse of a six well tissue culture plate.
After incubating the cultures overnight at 37.degree. C., 5%
CO.sub.2, the floating cells were removed from each culture.
Adherent cells were washed twice with 1.times. Phosphate Buffered
Saline (PBS). Each well of cells was fed 5 ml of complete DC media.
The cultures were incubated for 48 hours at 37.degree. C., 5%
CO.sub.2. The dendritic cells were harvested from the 6 well plate
by removing the supematant containing the cells to a 15 ml conical
centrifuge tube. Each well was washed twice with 3 ml of 1.times.
PBS. The cells were lightly trypsinized by adding 1 ml of 0.25%
Trypsin/EDTA (Gibco BRL) to each well. After rocking the plate to
cover the entire surface, the trypsin solution was quickly removed
from the plate. The plate was lightly tapped to remove any loosely
attaching cells. These cells were resuspended in 2 ml of complete
DC media and added to the 15 ml tube. The cells were pelleted by
centrifugation at 1500 rpm for five minutes. After resuspending the
cells in 10 ml of complete DC media, a cell count was taken.
[0065] B16F0 murine melanoma cells were obtained from the ATCC
(CRL-6322) and cultured using standard tissue culture techniques.
When the cells were ready for use, they were trypsinized using
0.25% Trypsin/EDTA. After taking a cell count the number of cells
needed for experimentation were pelleted by centrifugation at 1500
rpm for five minutes. The remaining cells were cultured for later
use.
[0066] For general cell membrane labeling of murine dendritic cells
and B16F0 melanoma cells, a commercial fluorescent cell linker kit
was used. The dendritic cells were labeled fluorescent green using
Sigma stock number PKH2-GL; the B16F0 melanoma cells were labeled
fluorescent red using Sigma stock number PKH26-GL. The staining
procedure was performed at 25.degree. C. The cells to be stained
were washed with serum-free media. The cell suspension was
centrifuged at 400 g for five minutes to obtain a loose pellet.
Supernatant was removed leaving less than 25 .mu.l of medium on the
pellet. The pellet was resuspended by tapping the tube, and 1 ml of
Diluent A or C for green or red staining respectively was added to
resuspend the cells. Immediately prior to staining,
4.times.10.sup.-6 molar dyes (2.times.) were prepared with Diluent
A or C in polypropylene tubes. To minimize ethanol effects, the
amount of dye added was less than 1% of the individual sample
volume. The cells in the diluent were rapidly added into 1 ml of
2.times. dye. The-cells and dye were immediately mixed by gentle
pipetting. The mixture was then incubated at 25.degree. C. for five
minutes. The staining process was stopped by adding an equal volume
of FBS and incubating for one minute. The stained cells were
diluted with equal volume of complete culture medium. Stained cells
were removed from the staining solution by centrifuging at 400 g
for 10 minutes. After a total of three washes, the cells were
resuspended in complete medium at a proper concentration.
Efficiency of staining was monitored by fluorescent microscopy.
[0067] Prior to the fusion process, the red fluorescently stained
B16F0 murine melanoma cells were irradiated with 5,000 rads. Murine
dendritic cells and B16F0 melanoma cells were fused together by
mixing the two cell types at a 1:1 ratio in a 50 ml conical
centrifuge tube. The tube was filled with serum-free RPMI 1640 with
25 mM Hepes. The cell mixture was centrifuged at 1500 rpm for five
minutes at room temperature. Note that during the fusion process,
all solutions as well as the tube in which the fusion was performed
were kept at 37.degree. C. using double-beaker water baths. The
supernatant from the mixed cell pellet was aspirated and discarded.
Using a 1 ml serological pipet, 1 ml of prewarmed 50% PEG/DMSO
(Sigrna), which contains 50% PEG and 10% DMSO in PBS (Ca.sup.++-
and Mg.sup.++-free), was added to the mixed cell pellet
drop-by-drop over one minute, stirring the cells with the pipet tip
after each drop. The mixture was stirred for an additional minute
with the pipet.
[0068] Using a clean 2 ml serological pipet, 2 ml of prewarmed
serum free RPNE 1640 with 25 mM Hepes was added to the cell mixture
drop-by-drop over two minutes, stirring after each drop. With a 10
ml serological pipet, 7 ml of prewarmed serum free RPMI 1640 with
25 mM Hepes was added drop-by-drop over two to three minutes. The
cells were pelleted by centrifugation at 1500 rpm for five minutes
at room temperature. The supernatant was discarded, and the tube
was placed back into the beaker wafer bath. With a clean 10 ml
serological pipet, the cell pellet was resuspended in 10 ml of
complete DC media by forcefully discharging about 3 ml of media
onto the pellet and then gently adding the remaining media. The
resuspended cells were put into a T75 tissue culture flask. The
Instant Dendritomas (fused dendritic cells with melanoma cells)
were incubated overnight at 37.degree. C., 5% CO.sub.2. A drop of
the cells was placed on a slide and evaluated by fluorescent
microscopy to ensure the occurrence of fusion.
[0069] The Instant Dendritomas were removed from the tissue culture
flask by saving the supematant containing the cells as well by
lightly trypsinizing the adherent cells as previously described.
The cells were pelleted by centrifugation at 1500 rpm for five
minutes. The cell pellet was resuspended in 2 ml of 1.times. PBS
and put into a sterile, polystyrene, round bottom, 12.times.75mm
Falcon tube. After centrifuging the cells at 1500 rpm for five
minutes, they were resuspended in 1 ml of 1.times. PBS. The Instant
Dendritomas were sorted out based on dual green and red
fluorescence using a FACS Caliber (Becton Dickinson), using
standard methods.
[0070] The sorted cells were pelleted by centrifugation at 2000 rpm
for 30 minutes. After removing the supernatant, the cells were
resuspended at a concentration of 50,000 cells/0.5 ml 1.times. PBS.
A drop of the cells was placed on a slide and evaluated by
fluorescent microscopy to ensure the general purity of the
sort.
[0071] Three days prior to the fusion process, female C57BL/6J mice
were challenged with 0.75.times.10.sup.6 B16F0 melanoma cells in
0.4 ml 1.times. PBS by intravenous injection. Once the Instant
Dendritomas were pelleted and resuspended, each mouse was injected
intravenously with 50,000 cells. This was followed by IL-2
treatment, which was administered intraperitoneally at 10,000
IU/day/mouse. The mice were monitored up to four weeks for
pulmonary metastasis.
[0072] At the end of four week, the mice were sacrificed and the
metastases were counted. Each of the four control animals, which
were not treated with the Instant Dendritomas, had greater that 50
tumors. On the other hand, only one of the treated animals had
measurable metastases. These data indicate that the present hybrid
cells are effective in treating cancer in proven animal model
system. The data are compiled in the following table.
1 Number of Metastases (including tumors GROUP at non-lung sites)
Control A >50 B >50 C >50 D >50 Experimental A 0 B 3 C
0 D 0
Example 2
Human Studies
[0073] This example demonstrates that the inventive dendritoma
hybrid cells induce a cancer cell-specific cytotoxic T cell
response. This offers proof of principle that these hybrid cells
can induce a therapeutically meaningful immune response against a
tumor.
[0074] In order to enhance the number of dendritic cells, which
were isolated from peripheral blood, a panning technique using
anti-CD14 coated plates was utilized. Five hundred micrograms of
anti-CD14 antibody was resuspended in 5 ml of 1.times. PBS with BSA
(700 .mu.g of BSA per 100 .mu.l of antibody). A 100 mm tissue
culture plate was coated with 5 mls of the antibody. The plate was
swirled and incubated for one hour at room temperature or overnight
at 4.degree. C. The antibody solution was removed, and the plate
was washed five times with 5 mls of 1.times. PBS.
[0075] Peripheral blood mononuclear cells (PBMC's) were isolated
from whole blood by obtaining 50 ml of peripheral blood from the
patient in preservative-free or sodium heparin tubes. The blood was
diluted 1:1 with 1.times. PBS. Eight ml of the diluted blood was
layered over 4 ml of room temperature Ficoll-Paque Plus in 15 ml
conical centrifuge tubes. The Ficoll gradients were centrifuged at
400 g at room temperature for 40 minutes. Using a Pasteur pipet,
the PBMC layers were carefully removed from the Ficoll gradient and
put into a clean 15 ml centrifuge tube. Four volumes of 1.times.
PBS were added to the tube and inverted several times to mix
thoroughly. The PBMC's were centrifuged at 100 g at room
temperature for 10 minutes. After removal of the supematant, 10 ml
of 1.times. PBS was added to the cell pellet and inverted to mix.
The PBMC's were pelleted by centrifugation at 100 g at room
temperature for 10 minutes. The supernatant was removed, and the
PBMC's were resuspended in 5 ml complete DC medium (RPMI 1640, 10%
Human Serum, 800U/ml GMCSF, 1000 U/ml IL-4, 100 .mu.g/ml
gentaaaicin).
[0076] The resuspended PBMC's (up to 2.times.10.sup.8) were
pipetted onto the anti-CD14 coated plate and swirled to cover the
entire plate. The plate was incubated at room temperature for 30
minutes. After gently swirling the plate again, the supematant
containing the non-adherent cells was removed. The adherent cells
were washed by adding 10 ml of 1.times. PBS and swirling. This wash
was repeated for a total of four times, pipetting at the same place
each time. Immediately after the washes, 10 mls of complete DC
media was added to the plate. The culture was incubated at
37.degree. C., 5% CO.sub.2 for 5 to 10 days to generate dendritic
cells.
[0077] A section of tumor that had been resected from a patient was
received immediatl after the surgery. The section of tumor was cut
into several pieces and placed in a 50 ml conical centrifuge tube
containing 1.times. PBS. The tumor pieces were further cut into
smaller pieces using sterile dissection scissors and placed into a
T75 tissue culture flask. Ten ml of 0.25% Trypsin/EDTA was added to
the flask, which was incubated at 37.degree. C. with rocking for
one hour. Following incubation, 15 ml of complete tumor cell
media.(DMEM, 10% Human Serum, 200 .mu.g/ml gentamicin) was added to
the flask. The tumor pieces were removed and placed into a clean
T75 flask, which was incubated overnight at 37.degree. C., 5%
CO.sub.2.
[0078] The medium/trypsin mixture from the original flask contained
some single tumor cells. These cells were filtered through a 40
.mu.m cell strainer and pelleted by centrifugation a 1500 rpm for
five minutes. The cells were resuspended in 10 ml of complete tumor
cell media and put into a T75 tissue culture flask and incubated at
37.degree. C., 5% CO.sub.2. To the flask containing the tumor
pieces, 20 ml of complete tumor cell media was added after the
overnight incubation. Both flasks were carefully monitored for
attaching cells. After several days, the tumor pieces were removed
from the flask. The attached tumor cells were fed every three days
and maintained for experimental use. They were subcultured using
standard tissue culture techniques for adherent cells.
[0079] Cell membrane labeling of human dendritic cells and tumor
cells were prepared as described in Example 1, above.
[0080] CD8+, cytotoxic T cells (CTLs) were prepared by the
following method. Peripheral blood mononuclear cells (PBMC's) were
isolated from whole blood by obtaining 40 ml of peripheral blood
from the patient in preservative-free or sodium heparin tubes and
10 ml in ACD tubes. The blood was diluted 1:1 with 1.times. PBS.
Eight ml of the diluted blood was layered over 4 ml of room
temperature Ficoll-Paque Plus in 15 ml conical centrifuge tubes.
The Ficoll gradients were centrifuged at 400 g at room temperature
for 40 minutes. Using a Pasteur pipet, the PBMC layers were
carefully removed from the Ficoll gradients and put into a clean 15
ml centrifuge tube. Four volumes of 1.times. PBS were added to the
tube and inverted several times to mix thoroughly. The PBMC's were
centrifuged at 100 g at room temperature for 10 minutes. After
removal of the supernatant, 10 ml of 1.times. PBS was added to the
cells and inverted to mix. The PBMC's were pelleted by
centrifugation at 100 g at room temperature for 10 minutes and
resuspended in complete lymphocyte media (RPMI 1640, 10% FBS, 100
.mu.g/ml gentamicin).
[0081] PBMC's were isolated from patients in preservative-free or
sodium hepaninized blood. They were subjected to the same panning
technique as previously described except that anti-CD4 antibody was
used to coat the plate. Prior to panning the PBMC's were enriched
for T lymphocytes by passing them through a nylon wool column. This
was done by packing 0.5 g of teased nylon wool into a 10 ml syringe
which has a stopcock attached to the tip. The column was washed
twice at 37.degree. C. with RPMI 1640 with 10% FBS. The stopcock
was closed and incubated at 37.degree. C. for one hour. After
draining the media from the column to the top of the wool, the
PBMC's were added to the column (up to 2.times.10.sup.8 in 2 ml of
media). The stopcock was opened the media was drained until the
cell volume had entered the packed wool. After closing the stopcock
additional media was added to cover the top of the wool. The column
was incubated for one hour at 37.degree. C. The nonadherent T cells
were collected by two media washes. After this T cell enrichment,
the T lymphocytes were panned using the anti-CD4 coated plate. T
cells that were not bound by the CD4 antibody were recovered and
assumed to be CD8+ cells (cytotoxic T lymphocytes). This was
confirmed by FACS analysis.
[0082] In order to have constant re-stimulators for tumor cell
specific CTL's, the PBMC's isolated from the ACD blood were
immortalized by Epstein-Barr virus (EBV) transformation. This was
accomplished by resuspending the PBMC's at a concentration of
1.times.10.sup.6 cells/ml complete lymphocyte media. To this, 1 ml
of EBV supernatant and 0.2 ml of phytohemagglutinin were added. The
cell mixture was cultured in a T25 tissue culture flask at
37.degree. C., 5% CO.sub.2.
[0083] The Instant Dendritomas obtained from the FACS sort were
mixed with the enriched, panned CD8+ T lymphocytes in a 1:10 ratio.
The CD8+ cells to be used were pelleted by centrifugation at 1500
rpm for five minutes and resuspended in 1 ml of medium containing
RPMI 1640, 10% FBS, 1000 U/ml IL-6, 5 ng/ml IL-12, and 10 U/ml
IL-2. This was added to the Instant Dendritomas plated after the
sort. This culture was incubated at 37? C., 5% CO.sub.2 for one
week. During that week the cells were refed with the same
media.
[0084] After one week, the primed CD8+ T cells (CTL's) were
restimulated with irradiated EBV-transformed lymphocytes that were
pulsed with tumor lysate. Tumor cells, which had been previously
cultured, were subjected to four freeze thaw cycles to lyse the
cells. To obtain the lysate containing tumor antigens, the lysed
cells were centrifuged at 600 g. for ten minutes. The supematant
was collected and centrifuged at 13,000 g for one hour. The
supernatant contain the lysate of tumor antigens was collected. To
restimulate the CTL's a viable cell count was taken using trypan
blue exclusion. Once the viable cell number was determined the same
number of EBV transformed lymphocytes were pulsed with the tumor
lysate by incubating the lysate with the lymphocytes at 37.degree.
C., 5% CO.sub.2 for one hour. The pulsed lymphocytes were
irradiated with 5,000 rads and then mixed with the CTL's in media
containing RPMI 1640, 10% FBS, 10 U/ml IL-1.alpha., 5 U/ml IL-2, 50
U/ml IL-4, 125 U/ml IL-6, and 30 U/ml IL-7. The culture was
incubated at 37.degree. C., 5% CO.sub.2 and refed every two days.
This re-stimulation was performed at 7 and 14 days after initial
prining.
[0085] Each day the CTL's were refed, the supernatant that was
removed was stored at -20.degree. C. When feasible, an
Interferon-gamma (IFN-.gamma.) assay was performed using an OptEIA
Human IFN-.gamma. Kit (PharMingen). The protocol was performed
exactly according to the manufacturer's directions. The assay was
read using a Benchmark Microplate Reader (BioRad).
[0086] To determine if the Instant Dendritomas stimulated a tumor
cell specific CTL response, a CTL assay was performed using the
cultured tumor cells as target cells. Fifty thousand tumor cells
were harvested and pelleted in a 15 ml conical centrifuge tube by
centrifugation at 200 g for five minutes. The supernatant was
discarded leaving 0.1 ml of medium on the pellet. The cells were
gently resuspended in the remaining medium. The tumor cells were
then labeled with .sup.51Cr by adding 0.1 ml of 1 mCi/ml .sup.51Cr
solution and 10 .mu.l FBS and mixing gently. This mixture was
incubated by loosening the cap of the tube and placing at
37.degree. C., 5% CO.sub.2 for one hour. After the incubation, the
labeled tumor cells were washed twice with 14 ml of RPMI 1640 and
resuspended at a concentration of 5.times.10.sup.4 cells/ml in
complete lymphocyte media.
[0087] The CTL effector cells were plated in 4 wells of a round
bottom 96 well tissue culture plate at concentrations that equaled
100:1, 30:1, 10:1, and 3:1 effector to target cell ratios. Five
thousand labeled target cells were added to the wells containing
the effector cells as well as two additional wells for natural and
maximum release controls. The cells were mixed and centrifuged at
200 g for 30 seconds. The plate was then incubated at 370 C, 5%
CO.sub.2 for four hours. Thirty minutes prior to the end of the
incubation, 0.1 ml of Triton X-100 was added to the maximum release
control well. At the end of the incubation, the cells were
centrifuged in the plate at 200 g for five minutes. 0.1 ml of each
supematant was added to liquid scintillation counter vials
containing 5 ml of scintillation cocktail. The amount of .sup.51Cr
release was measured using a LS6500 Multi-purpose Scintillation
Counter (Beckman).
[0088] The CTL assay results showed that as the ratio of hybrid
cell-primed CTLs to tumor cells increased, the release of the
isotope increased, indicating a positive correlation between the
number of CTLs and tumor killing. Greater than 50% killing was
observed at a 100:1 effector:target ratio. On the other hand, there
was no such correlation with control T cells that were not primed
with the inventive hybrid cells. Even at a ratio of 100:1, the
control T cells did not lyse more tumor cells than at lower ratios.
These results demonstrate that the CTLs generated using our hybrid
antigen presenting cells are fully functional and tumor cell
specific. The results are depicted in FIG. 1.
[0089] In fact, these data provide proof of the principal that the
present hybrid cells can be used in immunotherapy in vivo. CTLs are
known to play a vital role in the cell mediated immune response,
i.e., they are primarily responsible for killing the cells bearing
"foreign" antigens. A principle behind using immunotherapy to
treating cancer, for example, is based on stimulating tumor
cell-specific CTLs, which results in tumor cells killing. The fact
that the inventive hybrid cells are able to stimulate a
tumor-specific T cell response provides compelling evidence that
they will be useful in in vivo immunotherapy, via the same
mechanism.
Example 3
Dendritoma Characterization
[0090] This example provides further characterization of the
reactant cells and the dendritomas described in Examples 1 and
2.
[0091] Fluorescent microscopic analysis showed that 100% of the
stained cells were successfully labeled. To test whether the dye
can interstain between the two different type of cells, green DCs
and red tumor cells were mixed together and incubated overnight.
Fluorescent microscopic examination showed there was no
interstaining. Immediate examination of the fusion product
demonstrated that the green DCs and the red tumor cells were fused
together and after an overnight recovery, the fused cells showed
both colors. The double colored cells (approximately 10% of the
total cells), instant dendritomas, were then purified by FACS
sorting. More than 95% of the sorted cells were double colored
fused cells.
[0092] Instant dendritomas express all the molecules necessary for
antigen presentation. FACS analysis showed that instant dendritomas
express the molecules required for antigen presentation, such as
MHC class I and II and co-stimulating molecules CD80 (B7.1) and
CD86 (B7.2). The data are depicted in FIG. 2. "Isotype" is the
negative control; HLA-A,B,C is MHC class I and HLA-DR is MHC class
II. Under microscope, moreover, instant dendritomas also have those
dark granules that melanoma tumor cells have.
[0093] For FIG. 2, human DCs from peripheral blood were stained
with the green dye and tumor cells were stained with the red dye,
respectively, and fused, using the above-protocol. After overnight
incubation, the cells were equally divided into 4 groups. They were
then stained with Cy-Chrome conjugated antibodies by incubating the
cells with the antibodies (1 million cells/microgram antibody,
Becton/Dickinson) on ice for 30 min. The different groups were as
follows: anti-human HLA-A,B,C [group I]; anti-human HLA-DR [group
IU]; anti-human CD80 [group III]; and anti-human CD86 [group IV].
The un-bound antibodies were removed by two washes and the cell
pellet was re-suspended in 0.5 ml of staining buffer (PBS
containing 0.1% BSA and 0.1% sodium azide). Three-color analysis
was performed by FACS, using CellQuest software. Control human DCs
were also stained with the same antibodies in the same way.
Example 4
Clinical Protocol
[0094] This example provides an exemplary clinical protocol for
treating human cancer patients with the inventive hybrid cell
preparations. This regimen is useful, for example, to treat
melanoma patients with a dendritoma, prepared according to the
inventive methodologies.
[0095] Mature dentritic cells are generated from the patient's
peripheral blood monocytes. 50 mls of peripheral blood are obtained
from the patient in preservative free or sodium heparin tubes.
Briefly, the blood are diluted 1:1 with 1.times. PBS. Then, 8 mls
of the diluted blood are layered over 4 mls of room temperature
Ficoll-Paque Plus in a 15 ml centrifuge tube, and centrifuged at 40
g for 40 minutes. The PBMC layer is removed from the Ficoll
gradient, and placed into a clean 15 ml centrifuge tube. 4 volumes
of 1.times. PBS are added and the tube is inverted to mix. The
PBMC's are then centrifuged at 100 g at room temperature for 10
minutes. 10 mls of 1.times. PBS are added, and the cells are mixed
by inverting the tube. The PBMC's are again centrifuged at 100 g at
room temperature for 10 minutes. The PBMC's are resuspended in 5
mls complete DC medium (RPMI 1640+10% human serum+800 U/ml
GMCSF+1000 U/ml IL-4). Then the dendritic cells/precursors are
panned using anti-CD14 coated plates. 2.times.10.sup.8 PBMC's are
placed onto the anti-CD14 coated plate and swirled. They are left
to incubate at room temperature for 30 minutes. The non-adherent
cells are then removed. 10 mls of 1.times. PBS are added, the plate
is swirled, and the PBS is removed. This PBS washing is repeated
for a total of four times, pipetting at the same place each time.
Afterwards, 10 mls of complete DC media is added to the plate. They
are then incubated at 37.degree. C., 5% CO2 for 5-10 days to
generate dendritic cells.
[0096] A tumor section obtained at the time of biopsy or excisional
resection. The tumor cells are cultured using the following
technique. After separating fat and necrotic tissue away from the
tumor tissue (1-5 grams), the tumor are cut into small chunks and
put into a T 75 flask. 10 mls of 0.25% Trypsin-EDTA are added. This
solution will rock for 1 hour at 37.degree. C., and then 15 mls of
complete media (DMEM+10% human serum+gentamicin) are added. The
chunks are then removed and put into a clean T75 flask. This flask
is left at 37.degree. C. in 5% CO2 overnight. Then the cell
suspension/typsin/complete media is centrifuged at 1000 g for 5
minutes. These cells are resuspended in 15 mls of complete media
and cultured in a T75 flask at 37.degree. C. in 5% CO2 for 24
hours. After overnight incubation in the absence of media, 20 mls
of complete media are added to the flask with chunks, and this
solution is left for two days at 37.degree. C. in 5% CO2 The chunks
are removed, and the adherent cells are cultured. The tumor cells
used for dentritic fusion result from both cultures.
[0097] The next step involves the fusion of tumor cells and
dendritic cells received from the patient. Hybrid formation by cell
fusion became routine after the introduction of the use of
polyethylene glycol as a fusing agent. The procedure outlined below
is a variation of the one reported by Prado et al., 1989 FEBS
Lett., 259: 149-52., for the PEG-mediated fusion of somatic cells
in monolayers.
[0098] First, the tumor cells are exposed to a single dose of 5000
rads, sufficient to kill all of the cells. Then, the dendritic
cells are stained green using the PKH2-GL fluorescent dye (Sigma),
and the tumor cells are stained red using the PKH26 fluorescent-dye
(Sigma). The staining procedure is performed at 25.degree. C.,
using a slight modification of the Sigma procedure. The cells to be
stained are washed with serum-free media. The cell suspension is
centrifuged at 400 g for five minutes to obtain a loose pellet, and
the supematant fraction is removed. The pellet is resuspended by
tapping the centrifuge tube, and 1 ml of Diluent (20% DMSO in
serum-free RPMI) is added to resuspend the cells. Immediately prior
to staining, 4.times.10.sup.-6 molar dyes (2.times.) were prepared
with Diluent in polypropylene tubes. The cells in the diluent are
rapidly added into 1 ml of 2.times. dye, and the mixture is
immediately mixed by gentle pipetting. The mixture is then
incubated at 25.degree. C. for five minutes. The staining process
is stopped by adding an equal volume of 10% human serum, which may
be the patient's own serum, and incubating for one minute. The
stained cells are diluted with equal volume of complete culture
medium. Stained cells are removed from the staining solution by
centrifuging at 400 g for 10 minutes.
[0099] The green dendritic cells are mixed with the red tumor cells
at a 1:1 ratio in a 50-ml conical centrifuge tube. The tube is
filled with complete serum-free DMEM. The cell mixture is
centrifuged for 5 minutes at 500 g. While the cells are being
centrifuged, three 37.degree. C. double-beaker water baths are
prepared in the laminar flow hood by placing a 400-ml beaker
containing 100 ml of 37.degree. C. water into a 600-ml beaker
containing 75 to 100 ml of 37.degree. C. water. Tubes of prewarmed
50% PEG solution and complete serum-free DMEM are placed into two
of the 37.degree. C. water baths in the hood. Then, the supernatant
from the cell mixture is aspirated and discarded. The cell fusion
is performed at 37.degree. C. by placing the tube containing the
mixed-cell pellet in on of the double-beaker water baths in the
laminar flow hood. Then, 1 ml of prewarmed 50% PEG is added to the
mixed-cell pellet drop-by-drop over one minute, stirring the cells
with the pipette tip after each drop. The mixture is then stirred
for an additional minute.
[0100] Using a clean pipette, 1 ml of pre-warmed RPMI+HEPES is
added to the cell mixture drop-by-drop over one minute, stirring
after each drop. This step is repeated once with an additional 1 ml
of prewarmed RPMI+HEPES solution. With a 10-ml pipette, 7 ml of
prewarmed RPMI+HEPES is added drop-by-drop over 2 to 3 minutes.
This mixture is then centrifuged for five minutes at 500 g. While
the cells are in the centrifuge, the water baths are rewarmed to
37.degree. C. and placed in the hood. Prewarmed complete DC media
is placed in the beaker water bath. Then the supematant from the
mixture is discarded; the tube is placed in the beaker water bath.
With a pipette, 10 ml of prewarmed complete DC media are forcefully
discharged onto the cell pellet and placed in a T75 flask. This is
incubated overnight in a humidified 37.degree. C., 5% CO2
incubator.
[0101] The next day, the cells are analyzed on a FACS Caliber
fluorescence activated cell sorter using the CELLQuest software
(Becton/Dickerson), which will sort the fusion cells with both the
green and red dye. These fusion cells, dendritomas, are then
resuspended in 1 ml of NS (Normal Saline) and injected into the
patient.
[0102] The vaccine will consist of 100,000 (or more) irradiated
tumor cells fused to dentritic cells i.e. dendritomas. These
dendritomas are resuspended in 1 ml of NS and injected IV into the
patient
[0103] Interleukin 2 (e.g.,, Aldesleukin) also may be given in a
low-dose regimen. When used; IL-2 is administered by subcutaneous
injection in a dosage of 18 million units daily for 5 days
beginning on the day of vaccination.
* * * * *